Editas Medicine, Inc. Logo

Editas Medicine, Inc.

A clinical-stage genome editing company developing CRISPR medicines for serious diseases.

EDIT | US

Overview

Corporate Details

ISIN(s):
US28106W1036
LEI:
Country:
United States of America
Address:
11 HURLEY ST., 2141 CAMBRIDGE

Description

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative medicines for serious diseases using CRISPR technology. The company's mission is to discover, develop, and commercialize durable, precision genomic therapies that can correct the underlying genetic causes of various conditions. Its proprietary platform enables the precise revision, removal, or replacement of DNA. Editas Medicine's research and development pipeline is concentrated on creating both in vivo (in-body) and ex vivo (out-of-body) gene-edited medicines to treat a broad class of diseases, with a focus on rare genetic disorders.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Editas Medicine, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Editas Medicine, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Editas Medicine, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Genprex, Inc. Logo
Clinical-stage gene therapy company developing therapies for cancer and diabetes.
United States of America
GNPX
Genxone Spolka Akcyjna Logo
A biotechnology company specializing in Next Generation Sequencing and medical diagnostics.
Poland
GX1
GeoVax Labs, Inc. Logo
Clinical-stage biotech developing vaccines and therapies for infectious diseases and cancer.
United States of America
GOVX
GH Research PLC Logo
Develops mebufotenin-based therapies for psychiatric and neurological disorders.
United States of America
GHRS
GI Innovation Inc. Logo
Researches and develops protein-based drugs for immuno-oncology and immunology.
South Korea
358570
Ginkgo Bioworks Holdings, Inc. Logo
Operates a horizontal platform for cell programming and synthetic biology.
United States of America
DNA
GRAIL, Inc. Logo
A healthcare company developing blood tests for multi-cancer early detection.
United States of America
GRAL
GT Biopharma, Inc. Logo
Clinical-stage immuno-oncology company developing therapies with its NK cell engager tech.
United States of America
GTBP
Guard Therapeutics International AB Logo
Clinical-stage biotech developing therapies to prevent acute kidney injury.
Sweden
GUARD
Gubra A/S Logo
Biotech and CRO focused on peptide drugs for metabolic and fibrotic diseases.
Denmark
GUBRA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.